Tarestumab OMP 59R5 represents a promising therapeutic agent targeting Notch-2 , a important receptor implicated in several neoplastic diseases. This human immunoglobulin selectively binds to Notch-2 , blocking its activation and demonstrating early promise in several settings of hematological m